These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20093557)

  • 1. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
    Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I
    Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Tiss A; Timms JF; Smith C; Devetyarov D; Gentry-Maharaj A; Camuzeaux S; Burford B; Nouretdinov I; Ford J; Luo Z; Jacobs I; Menon U; Gammerman A; Cramer R
    Int J Gynecol Cancer; 2010 Dec; 20(9):1518-24. PubMed ID: 21370595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
    Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
    Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
    Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
    BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
    Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
    [No Abstract]   [Full Text] [Related]  

  • 6. Profiling of Serum Metabolites Using MALDI-TOF and Triple-TOF Mass Spectrometry to Develop a Screen for Ovarian Cancer.
    Lee JH; Kim YH; Kim KH; Cho JY; Woo SM; Yoo BC; Kim SC
    Cancer Res Treat; 2018 Jul; 50(3):883-893. PubMed ID: 28934848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
    Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X
    Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential serum peptide biomarkers of biliary tract cancer using MALDI MS profiling.
    Sandanayake NS; Camuzeaux S; Sinclair J; Blyuss O; Andreola F; Chapman MH; Webster GJ; Smith RC; Timms JF; Pereira SP
    BMC Clin Pathol; 2014 Feb; 14(1):7. PubMed ID: 24495412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
    Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
    Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.
    Lopez MF; Mikulskis A; Kuzdzal S; Golenko E; Petricoin EF; Liotta LA; Patton WF; Whiteley GR; Rosenblatt K; Gurnani P; Nandi A; Neill S; Cullen S; O'Gorman M; Sarracino D; Lynch C; Johnson A; Mckenzie W; Fishman D
    Clin Chem; 2007 Jun; 53(6):1067-74. PubMed ID: 17463175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
    Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
    Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
    Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
    Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
    Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
    Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.
    Timms JF; Menon U; Devetyarov D; Tiss A; Camuzeaux S; McCurrie K; Nouretdinov I; Burford B; Smith C; Gentry-Maharaj A; Hallett R; Ford J; Luo Z; Vovk V; Gammerman A; Cramer R; Jacobs I
    Cancer Genomics Proteomics; 2011; 8(6):289-305. PubMed ID: 22086897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential exoprotease activities confer tumor-specific serum peptidome patterns.
    Villanueva J; Shaffer DR; Philip J; Chaparro CA; Erdjument-Bromage H; Olshen AB; Fleisher M; Lilja H; Brogi E; Boyd J; Sanchez-Carbayo M; Holland EC; Cordon-Cardo C; Scher HI; Tempst P
    J Clin Invest; 2006 Jan; 116(1):271-84. PubMed ID: 16395409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of candidate biomarker mass (m/z) ranges in serous ovarian adenocarcinoma using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.
    Periyasamy A; Gopisetty G; Veluswami S; Joyimallaya Subramanium M; Thangarajan R
    Biomarkers; 2015; 20(5):292-8. PubMed ID: 26329525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures.
    Velstra B; van der Burgt YE; Mertens BJ; Mesker WE; Deelder AM; Tollenaar RA
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):1983-92. PubMed ID: 22763645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
    Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
    Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.
    Velstra B; Vonk MA; Bonsing BA; Mertens BJ; Nicolardi S; Huijbers A; Vasen H; Deelder AM; Mesker WE; van der Burgt YE; Tollenaar RA
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):531-41. PubMed ID: 25240825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study for drug-resistance of epithelial ovarian cancer by serum protein profiling].
    Zhang WY; Zhu LR; Zheng YH; Zhou L; Zhang JZ; Wu JH; Liao QP
    Zhonghua Yi Xue Za Zhi; 2009 May; 89(19):1326-9. PubMed ID: 19615186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.